TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Tacrolimus as Treatment of Breast Cancer-Related Lymphedema

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 30-65 years~* Female~* Lymphedema diagnosis as a result of breast cancer treatment~* Active Lymphedema (excessive fluid)~* Significant lymphedema~* Grade I-II lymphedema~* Postmenopausal (Absence/lack of menstruation in at least 12 consecutive months) or continuously usage of contraceptive drugs (Spiral, birth-control pills, implant, transdermal patches, vaginal ring or depot injection). Contraceptive drugs must be used throughout the project and at least three weeks subsequent to the ending of the project (last application of the ointment).~* Clinically good general condition No lymphedema in the opposite arm (normal arm)~* Understands the purpose og the study and gives written consent to participate~* Can read and understand the danish language~Exclusion Criteria:~* Pregnant, breast-feeding or with wish of pregnancy within the next year~* Bilateral breast cancer~* Grade 0, III or IV lymphedema~* Known allergies for Tacrolimus or and other macrolide~* Removal of lymph nodes in the opposite armpit~* Suffers from psychiatric disorders that may affect the participation in the project~* Reduced kidney or liver function~* Defect skin-barrier~* Diagnosed immunodeficiency

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Women with stage 1-2 lymphedema due to breast cancer treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ambrisentan in Single Ventricle

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 24 months; ≤120 months.~2. History of congenital heart disease with severe hypoplasia of a right or left ventricle.~3. Undergoing Fontan surgery as part of standard clinical care.~4. Availability and willingness of the parent/legally authorized representative to provide written informed consent and, as appropriate, assent from the child.~Exclusion Criteria:~1. History of serious adverse event related to ambrisentan administration.~2. History of ambrisentan exposure within 48 hours of the study.~3. Presence of pulmonary venous obstruction.~4. Treatment with cyclosporin.~5. Any of the following - as determined by the attending physician~   * Significant hemodynamic instability~  * Sepsis.~  * Need for ECMO support.~6. Renal failure defined as serum creatinine \> 2 times higher than the upper limit of normal.~7. Liver dysfunction defined as alanine aminotransferase or aspartate aminotransferase \> 3 times higher than the upper limit of normal.~8. Thrombocytopenia defined as a platelet count \< 50 000 cells/µL.~9. Leukopenia defined as white blood cells \< 2500 cells/µL.~10. Anemia defined as hemoglobin \< 8mg/dL.~11. Atrial hypertension (mean LA pressure \> 12mm Hg).

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: 120 Months
- Healthy Volunteers: f

Study Arms:
- Ambrisentan (Type: ACTIVE_COMPARATOR): Oral ambrisentan 2.5 - 5 mg, single dose, once daily
- Placebo (Type: PLACEBO_COMPARATOR): Oral placebo 2.5 - 5 mg, single dose, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - Informed consent obtained before any trial related activities. Trial related activities are any procedures that are carried out as part of the trial, including activities to determine the suitability for the trial - Male haemophilia A or B patients with inhibitors aged 18 years or older at the time of signing informed consent - Patients currently in need of treatment with bypassing agents Exclusion Criteria: - Known or suspected hypersensitivity to trial product(s) or related products - Known inherited or acquired bleeding disorder other than haemophilia - Ongoing or planned immune tolerance induction therapy or prophylaxis with FVIII or FIX

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Concizumab (Type: EXPERIMENTAL): Concizumab administered in both the main phase and extension phase, with eptacog alfa administered on-demand during bleeding episodes
- Eptacog alfa and concizumab (Type: ACTIVE_COMPARATOR): Eptacog alfa administered on-demand during bleeding episodes as the only intervention during the main phase. Concizumab given in the extension phase

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have not taken the following treatments within the indicated duration and agree not to use at any time during the study:~  * All other Benign Prostatic Hyperplasia (BPH) therapy (including herbal preparations) for at least 4 weeks prior to receiving study medication.~ * Overactive bladder therapy (including antimuscarinics) for at least 4 weeks prior to receiving study medication.~ * Erectile Dysfunction therapy (including herbal preparations) for at least 4 weeks prior to receiving study medication.~ * Finasteride or dutasteride use at any time.~* Have bladder outlet obstruction as defined by a urinary peak flow rate (Qmax) of greater than or equal to 4 and less than or equal to 15 milliliters (mL)/second before receiving study drug.~* Have prostate enlargement measured by ultrasound at screening.~Exclusion Criteria:~* Have prostate cancer, are being treated for cancer or have clinical evidence of prostate cancer \[Prostate-specific antigen (PSA) greater than 10 nanograms/milliliter (ng/mL) at the start of study\].~* Have had any of the following in the past 90 days: Heart attack, also known as a myocardial infarction (MI); Heart bypass surgery (called coronary artery bypass graft surgery); Had a procedure to open up blood vessels in the heart known as angioplasty or stent placement (percutaneous coronary intervention).~* Have problems with kidneys, liver, or nervous system~* Have uncontrolled diabetes~* Have had a stroke or a significant injury to brain or spinal cord.~* Have scheduled or planned surgery during the course of the study.

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tadalafil (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effect of Montelukast Sodium With Concomitant Administration of Inhaled Budesonide in Asthmatic Patients (0476-075)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males or females between the ages of 18 and 70 with asthma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a history of classical Hodgkin's lymphoma that has progressed after high-dose chemotherapy and Autologous Stem cell transplant and/or after gemcitabine- or vinorelbine- or vinblastine-based treatment~* Patients with at least one site of measurable disease measuring ≥ 2.0cm confirmed by PET and CT Scan (or MRI)~* Patients with adequate bone marrow, liver and renal function (confirmed by laboratory values)~* Patients with fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN~Exclusion Criteria:~* Previous treatment with mTOR inhibitors~* Prior allogeneic stem cell transplant~* Chemotherapy, monoclonal antibody therapy, major surgery or treatment with other investigational drugs within 4 weeks of starting study treatment~* Another malignancy within 3 years of study entry (except adequately treated non-melanoma skin cancer and carcinoma in situ of the cervix)~* Severe and/or uncontrolled medical conditions that could affect participation in this study~* Female patients who are pregnant or breastfeeding; patients who are not willing to use adequate birth control during the study and for 8 weeks after the last study treatment Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RAD001 (Type: EXPERIMENTAL): Patients with a history of classical Hodgkin lymphoma (ie, nodular sclerosing, mixed cellularity, lymphocyte-rich, lymphocyte-depleted) whose disease had progressed after receiving high-dose chemotherapy with AHSCT (if eligible) and/or after therapy with a gemcitabine- or vinorelbine- or vinblastine-containing regimen, were enrolled into this study. All patients were assigned to a daily dose of everolimus 10 mg (two 5-mg tablets), selfadministered orally and continuously from Cycle 1 Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death, or discontinuation from the study for any other reason.~A treatment cycle consisted of 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hyoscine Butylbromide for Prevention of Bradycardia During Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status class I-II.~* Age: 18 Years to 40 Years.~* Women scheduled for elective Cesarean section under spinal anesthesia.~* indications for CS other than fetal or maternal pathology.~Exclusion Criteria:~* Height \< 150 or \> 180 cm~* Body mass index (BMI) \>35 kg/m2~* Contraindication for central neuraxial block~* Refusal to undergo regional anesthesia~* Known allergy to any of the study drugs,~* Infection at the site of injection,~* Coagulopathy,~* Indication to general anesthesia~* Baseline bradycardia (heart rate \< 60/min), or any cardiovascular disease~* Patients taking β-adrenergic blockers or any drugs that may alter normal response to study drugs.~* Arrhythmia such as atrial fibrillation, supraventricular tachycardia, heart block greater than first degree, left bundle branch block,~* Hypertension (systolic blood pressure more than 140 mm Hg or diastolic blood pressure more than 90 mm Hg), unstable angina or cardiomyopathy,~* Associated medical problem with pregnancy (as hypertension, diabetes mellitus, hepatic impairment or renal impairment)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Hyoscine butylbromide (Type: ACTIVE_COMPARATOR): None
- Control (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects have primary diagnosis of ADHD~* Females of childbearing potential must have a negative serum beta Human Chorionic Gonadotropin (HCG) pregnancy test~* Subject has an IQ score of \>_ 80~* Subject is able to complete as least the Basic Test of the PERMP assessment~Exclusion Criteria:~* Subject has a comorbid psychiatric diagnosis such as Axis II disorders or severe Axis I disorders~* Subject is taking Strattera(r)~* Subject has a recent history of suspected substance abuse or dependence disorder

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate Transdermal System (Type: ACTIVE_COMPARATOR): The duration of MTS patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
- Placebo (Type: PLACEBO_COMPARATOR): The duration of placebo patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
- Concerta (Type: ACTIVE_COMPARATOR): CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessing a Novel Virtual Environment That Assists With Activities of Daily Living

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~The subject will have a diagnosis of AD/ADRD, or symptoms of an undiagnosed AD/ADRD as observed by professional care staff and confirmed by the head of clinical care. The investigators will neither include nor exclude participation based on cognitive test scores. The subject will have had challenge(s) completing one or more ADLs in the previous month, as discussed at staff meetings, referenced in care plans, or observed/experienced by direct care staff.~Other specifications:~* Understand English or Russian.~* Can sit comfortably for at least 15 minutes in a chair/wheelchair at a table or propped up in bed or princess chair with a tray table~* Are not known to be in pain~* Have good vision, or good corrected vision (i.e., glasses)~* Have good hearing, or good corrected hearing (i.e., aids)~* May sometimes have anxiety or agitation when undertaking ADLs.~Exclusion:~Ineligible subjects are those with significant non-AD/ADRD neurological, psychiatric, or physical impairment or those who are totally dependent upon others for ADLs.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 110 Years
- Healthy Volunteers: f

Study Arms:
- Persons residing in long-term care homes (Type: EXPERIMENTAL): Subjects' ADLs are studied with intervention compared to baseline (without intervention).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: McGrath Videolaryngoscopy and Direct Laryngoscopy in Morbidly Obese Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective surgery requiring oral endotracheal intubation for general anesthesia;~* Anticipated extubation in the operating room;~* American Society of Anesthesiologists (ASA) physical status 1-3;~* Age between 18 and 99 years;~* Body Mass index ≥ 40 kg/m2.~Exclusion Criteria:~* Refusal of participation by attending anesthesiologist;~* Indicated rapid sequence induction for any reason including, but not limited to high risk of aspiration~* Indicated fiberoptic awake intubation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- McGrath videolaryngoscopy (Type: EXPERIMENTAL): Endotracheal intubation using McGrath videolaryngoscopy in an appropriate size (usually blade size 3 or 4)
- Direct laryngoscopy (Type: ACTIVE_COMPARATOR): Endotracheal intubation using direct laryngoscopy with an appropriately sized Macintosh blade (usually size 3 or 4)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Myocardial Protection of Exenatide in AMI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 20 and 79 years~* patients presenting with first ST-segment elevation myocardial infarction~* Thrombolysis in Myocardial Infarction \[TIMI\] flow grade 0)~Exclusion Criteria:~* cardiac arrest~* ventricular fibrillation~* cardiogenic shock~* hemodynamic instability~* suspicious stent thrombosis~* left bundle branch block~* previous acute myocardial infarction~* previous coronary artery bypass operation~* significant valvular heart disease~* primary myocardial disease~* atrial fibrillation~* significant hepatic or renal dysfunction, hypoglycaemia,~* diabetic ketoacidosis~* active infection or chronic inflammatory disease~* malignancy~* women who were pregnant or who were of childbearing age

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: ACTIVE_COMPARATOR): Drug: Exenatide~10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days.
- Saline (Type: PLACEBO_COMPARATOR): Drug: Saline~10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Nasal Steroids After FESS in CRSwNP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients who have had FESS for CRSwNP within the study period~Exclusion Criteria:~1. Patients who are under the age of 18~2. Concurrent oral corticosteroid use of the equivalent of greater than 10 mg of prednisone use per day~3. The use of medications that accelerate the clearance of systemic cortisol (Dilantin, rifampin, amphetamines, and lithium)~4. The use of medications that inhibit the clearance of systemic cortisol (ketoconazole, amphotericin B, bupropion, fluoroquinolones)~5. Known hypersensitivity to corticosteroids~6. A personal history of Wegener's Granulomatosis or other autoimmune disease with nasal manifestations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- fluticasone nasal spray (Type: ACTIVE_COMPARATOR): Group one will be prescribed fluticasone nasal spray ( to use 2-50 mcg sprays to each nostril two times per day)
- budesonide respule in head upright (Type: ACTIVE_COMPARATOR): Group two will be prescribed budesonide respules (0.5 mg/2mL) to instill into each nostril in the upright position two times per day
- budesonide head forward (Type: ACTIVE_COMPARATOR): Group three will be prescribed budesonide respules (0.5 mg/2mL) to use instill into each nostril in the head forward position two times per day with their head angled downwards by having their head lean forward off the side of a bed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete